# An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

> **NCT04563338** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 36 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Non-small Cell Lung Cancer Metastatic
- Liver Metastases

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04563338
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-04
- **Primary completion:** 2024-06-25
- **Final completion:** 2026-08-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04563338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04563338, "An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04563338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*